HER2+ Metastatic Breast Cancer (MBC) Active Not Recruiting Phase 3 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0062591 (HER2+ Metastatic Breast Cancer (MBC))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs